REVISTA ARGENTINA DE
MICROBIOLOGÍA

ORIGINAL ARTICLE

Diversity of *Achromobacter* species recovered from patients with cystic fibrosis, in Argentina

Mariana Papalia [a,f], **Carla Steffanowski** [a], **Germán Traglia** [b,f], **Marisa Almuzara** [b],
Pablo Martina [c,f], **Laura Galanternik** [d], **Carlos Vay** [b], **Gabriel Gutkind** [a,f],
María Soledad Ramírez [e,f], **Marcela Radice** [a,f,*]

[a] *Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Microbiología, Laboratorio de Resistencia Bacteriana, Ciudad Autónoma de Buenos Aires, Argentina*
[b] *Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Hospital de Clínicas José de San Martín, Departamento de Bioquímica Clínica, Laboratorio de Bacteriología Clínica, Ciudad Autónoma de Buenos Aires, Argentina*
[c] *Universidad Nacional De Misiones, Instituto de Biología Subtropical, Misiones, Argentina*
[d] *Hospital de Niños Ricardo Gutiérrez, Ciudad Autónoma de Buenos Aires, Argentina*
[e] *California State University, Fullerton, Department of Biological Science, Fullerton, United States*
[f] *Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina*

Abstract Different phenotype-based techniques and molecular tools were used to describe the distribution of different *Achromobacter* species in patients with cystic fibrosis (CF) in Argentina, and to evaluate their antibiotic resistance profile. Phenotypic identification was performed by conventional biochemical tests, commercial galleries and MALDI-TOF MS. Genetic approaches included the detection of *A. xylosoxidans* specific marker $bla_{\text{oxa-114}}$, the amplification and sequencing of the 16S rRNA gene, *nrdA* and bla_{OXA} complete sequence, and MLST analysis. Phenotypic approaches, even MALDI-TOF, rendered inconclusive or misleading results. On the contrary, concordant results were achieved with the *nrdA* sequencing or sequence type (ST) analysis, and the complete bla_{OXA} sequencing, allowing a reliable discrimination of different *Achromobacter* species. *A. xylosoxidans* accounted for 63% of *Achromobacter* infections and *A. ruhlandii* accounted for 17%. The remaining species corresponded to *A. insuavis*, *A. dolens*, *A. marplatensis* and *A. pulmonis*. Antimicrobial susceptibilities were determined by the agar dilution method according to CLSI guidelines. Piperacillin, piperacillin/tazobactam and carbapenems were the most active antibiotics. However, the emergence of carbapenem-resistant isolates was detected. In conclusion, prompt and accurate identification tools were necessary to

* Corresponding author.
  E-mail address: mradice@ffyb.uba.ar (M. Radice).

determine that different *Achromobacter* species may colonize/infect the airways of patients with CF. Moreover, antimicrobial therapy should be administered based on the susceptibility profile of individual *Achromobacter* sp. isolates.

Diversidad de las especies de *Achromobacter* recuperadas de pacientes con fibrosis quística en Argentina

Resumen   Se emplearon diversas técnicas fenotípicas y moleculares para describir la distribución de diferentes especies del género *Achromobacter* en pacientes con fibrosis quística (FQ) en Argentina, y se evaluó el perfil de resistencia a los antibióticos. Se realizó la identificación fenotípica por pruebas bioquímicas convencionales, galerías comerciales y MALDI-TOF MS. El enfoque genético incluyó la detección del marcador especie-específico de *A. xylosoxidans* $bla_{oxa-114}$, la amplificación y la secuenciación de los genes ARNr 16S, *nrdA* y secuencia completa de bla_{OXA}, y el análisis por MLST. Los enfoques fenotípicos, incluso la técnica de MALDI-TOF, proporcionaron resultados no concluyentes o erróneos. Por el contrario, se obtuvieron resultados concordantes entre la secuenciación del gen *nrdA* o el análisis de secuenciotipos (ST) y la secuenciación completa de bla_{OXA}, lo que permitió una discriminación confiable de las diferentes especies de *Achromobacter*. *A. xylosoxidans* representó el 63% de las infecciones por *Achromobacter* y *A. ruhlandii* representó el 17%. Las especies restantes correspondieron a *A. insuavis*, *A. dolens*, *A. marplatensis* y *A. pulmonis*. Se determinó la sensibilidad a antimicrobianos por el método de dilución en agar de acuerdo al CLSI. Los antibióticos más activos fueron piperacilina, piperacilina/tazobactam y carbapenemes. Sin embargo, se detectó la emergencia de aislamientos resistentes a carbapenemes. En conclusión, resultaron necesarias herramientas de identificación rápida y precisas para determinar las diferentes especies del género *Achromobacter* capaces de colonizar/infectar las vías respiratorias de los pacientes con FQ. Asimismo, la terapia antimicrobiana debería llevarse a cabo en función del perfil de sensibilidad de los aislamientos individuales de *Achromobacter* spp.

Introduction

Achromobacter spp. are increasingly recognized as emerging pathogens in patients with cystic fibrosis (CF)[20]. Reported rates of *Achromobacter* colonization/infection in individuals with CF, vary between 2% and 17.9%, and display a rising tendency worldwide[3,10]. *Achromobacter xylosoxidans* is the most frequent species recovered within this genus, however other species have been associated with human infections[15,17]. Moreover, clinical isolates are mostly referred as *A. xylosoxidans* given that the accurate species identification of *Achromobacter* isolates is difficult.

Conventional phenotypic methods have been commonly used for bacterial identification of *Achromobacter* spp. in many clinical laboratories, as their implementation and cost make them more affordable. Since these classical methods yield unclear results, and generally fail to differentiate between species of the genus, molecular methods have been proposed as complementary or alternative procedures.

Amplification and sequencing of the 16S rRNA coding gene, which constitutes a useful method in the identification of numerous microorganisms, is not able to discriminate between species of *Achromobacter*[5,12]. In 2011, Turton et al. proposed the amplification of the $bla_{OXA-114}$ gene for rapid and accurate *A. xylosoxidans* identification[9,21]. Moreover, in 2013 we described the presence of $bla_{OXA-258}$, $bla_{OXA-364}$, and $bla_{OXA-243}$ in *Achromobacter ruhlandii*, *Achromobacter dolens*, and *Achromobacter insuavis*, respectively, as species-specific markers useful for bacterial identification[14,19]. Simultaneously, Spilker et al. proposed the amplification and sequencing of an inner fragment of the *nrdA* gene, one of those included in the multilocus sequence typing (MLST) scheme, as a precise method for the identification of different species of *Achromobacter*[17].

MALDI-TOF MS has emerged as a revolutionary technique for rapid bacterial identification. This method has been shown to be more rapid, accurate and cost-efficient than conventional phenotypic techniques or genotypic approaches. However, its performance is uncertain in infrequent species.

In this study, different phenotype-based techniques and molecular tools were conducted to describe the distribution of different species of *Achromobacter* in patients with

CF in Argentina, and to evaluate their antibiotic resistance profile.

Methods

Isolates

Forty-one non-related *Achromobacter* spp. clinical isolates, recovered from patients with CF at 6 healthcare centers in Argentina during 1996–2013 were included. Isolates were mainly obtained from respiratory secretions (Table S1, supplementary material).

Phenotypic identification

Phenotypic identification was performed by biochemical tests according to Yabuuchi et al.[23] and Vandamme et al.[22] The biochemically-based commercial system, API 20NE (bioMèrieux) was also conducted.

MALDI-TOF MS identification was performed using a Microflex MALDI-OF MS instrument (Bruker Daltonics, GmbH, Germany) and FlexControl 3.0 software (Bruker Daltonics). Identification scores ≥2.0 were accepted for a reliable identification at species level and scores between ≥1.7 and ≤2.0 were accepted for identification at genus level. Scores <1.7 indicated no reliable identification[8].

Genotypic identification

The 16S rRNA gene was amplified by PCR as previously described[13]. Purified amplicons were sequenced in both strands using an ABI Prism DNA 3700 sequencer and compared with databases using the NCBI's BLAST tool.

The *nrdA* sequence was achieved according to Spilker et al. and compared with databases (https://pubmlst.org/achromobacter/)[17].

The presence of *A. xylosoxidans* species-specific marker, $bla_{OXA-114}$, was investigated by PCR amplification as previously described by Turton et al.[21] The complete $bla_{OXA-114}$, $bla_{OXA-258}$, $bla_{OXA-364}$ and $bla_{OXA-243}$ sequences intrinsic for *A. xylosoxidans*, *A. ruhlandii*, *A. dolens*, and *A. insuavis*, respectively, were amplified according to Traglia et al.[19] Amplicon sequences were compared with those of all the different bla_{OXA} variants deposited in GenBank.

Multilocus sequence typing analysis

A multilocus sequence typing (MLST) scheme was conducted to identify those isolates which could not be unambiguously identified by *nrdA* sequencing. For this purpose, amplification and sequencing of inner fragments of seven housekeeping genes were performed and the corresponding allele profiles and sequence types (ST) were assigned according to the *Achromobacter* MLST website (http://pubmlst.org/achromobacter/)[18].

Antimicrobial susceptibility testing

Minimal inhibitory concentrations (MIC) were determined for a representative set of antibiotics: ampicillin, piperacillin, cefoxitin, ceftazidime, cefepime, piperacillin/tazobactam, imipenem, meropenem, ciprofloxacin, levofloxacin, amikacin, kanamycin, gentamicin, trimethoprim-sulfamethoxazole, tetracycline and colistin. Antimicrobial susceptibilities were determined by the agar dilution method according to Clinical and Laboratory Standards Institute (CLSI) recommendations. The susceptibility breakpoints used in this study were those established for other non-*Enterobacteriaceae*[6].

Results

Phenotypic identification results are shown in Table S1. According to classical biochemical methods, 27/41 isolates were identified as *A. xylosoxidans*, the remaining ones being identified as *Achromobacter* spp. Using the API 20NE commercial gallery, 39/41 corresponded to *A. xylosoxidans*. Based on MALDI-TOF MS data, all isolates except one were consistent with *A. xylosoxidans*. Species identification was achieved in 25/40 isolates with score ≥2, while 15/40 displayed scores from 1.7 to 1.9. None of the samples presented score <1.7.

The 16S rRNA sequences obtained for the isolates included in this study displayed about 99% identity with those deposited for different species of *Achromobacter*, being unable to discriminate among them.

The results of the other genetic approaches performed in this study are shown in Table 1. The amplification of $bla_{OXA-114}$ proposed by Turton et al.[21] yielded positive results in 39/41 isolates, indicating that they corresponded to *A xylosoxidans*. However discrepancies were observed in 13/39 isolates when comparing these results with those obtained using other molecular methods. Based on these methods, the 13 isolates were finally identified as *Achromobacter* species other than *A. xylosoxidans* (Table 1).

nrdA gene sequencing[17] allowed to identify 33/41 isolates. In the remaining isolates, *nrdA* sequences corresponded to alleles that were not deposited in pubmlst.org/achromobacter. For these isolates, identification was performed based on the complete MLST Scheme[18]. Different alleles of $bla_{OXA-114}$ were observed in the 26 isolates identified as *A. xylosoxidans* by *nrdA* gene sequencing[17]; even, 3 new $bla_{OXA-114}$ variants were identified in this study (accession numbers: MK388911, MK388912, MK388913) (Table 1). These new $bla_{OXA-114}$ variants were designated as OXA-114i, OXA-790 and OXA-791 by NCBI. Then again, in those isolates identified as *A. insuavis*, *A. dolens* and *A. ruhlandii* by *nrdA* gene sequencing or ST analysis, the bla_{OXA} sequences displayed 99–100% identity to $bla_{OXA-243}$, $bla_{OXA-364}$ and $bla_{OXA-258}$, respectively. Two new $bla_{OXA-364}$ variants were identified (MK388909, MK388910) (Table 1). These $bla_{OXA-364}$ variants were designated as OXA-787 and OXA-789 by NCBI. No bla_{OXA} amplicons could be obtained in any of the isolates identified by *nrdA* sequencing[17] as *Achromobacter marplatensis* and *Achromobacter pulmonis* (Table 1).

A. xylosoxidans accounted for 63.4% of *Achromobacter* colonization/infections in this study, while *A. ruhlandii* accounted for 17.1%. The remaining species corresponded to *A. dolens* (9.8%), *A. insuavis* (4.9%), *A. marplatensis* (2.4%) and *A. pulmonis* (2.4%). According to previous studies performed in the UK[7], Spain[4], France[2], USA[17], Brazil[16]

Table 1 Comparison of different genotypic methods for the identification of *Achromobacter* spp. isolates

Isolate	Year of isolation	*nrdA* analysis[17] and ST	PCR *bla*$_{OXA}$[21]	*bla*$_{OXA}$[19]
A39	2008	*A. xylosoxidans*	+	*bla*$_{OXA-114m}$
A43	2009	*A. dolens*	+	*bla*$_{OXA-787}$ (MK388909)
A45	2011	*A. pulmonis*	−	–
A46	2011	*A. marplatensis*	−	–
A49	2012	*A. xylosoxidans*	+	*bla*$_{OXA-790}$ (MK388911)
A50	2012	*A. dolens*	+	*bla*$_{OXA-789}$ (MK388910)
A51	2012	*A. xylosoxidans*	+	*bla*$_{OXA-114o}$
A52	2004	*A. xylosoxidans*	+	*bla*$_{OXA-791}$ (MK388912)
A53	2012	*A. dolens*	+	*bla*$_{OXA-364a}$
A79	2012	*A. xylosoxidans*	+	*bla*$_{OXA-114i}$ (MK388913)
A113	2009	*A. xylosoxidans*	+	*bla*$_{OXA-790}$ (MK388911)
A131	2012	*A. ruhlandii*	+	*bla*$_{OXA-258a}$
A134	2013	*A. ruhlandii*	+	*bla*$_{OXA-258a}$
38	2002	ST 148 (*A. ruhlandii*)[a]	+	*bla*$_{OXA-258a}$
39	2002	ST 148 (*A. ruhlandii*)[a]	+	*bla*$_{OXA-258a}$
67	2004	ST 148 (*A. ruhlandii*)[a]	+	*bla*$_{OXA-258a}$
79	2004	ST 64 (*A. insuavis*)[a]	+	*bla*$_{OXA-243a}$
80	2004	ST 14 (*A. ruhlandii*)[a]	+	*bla*$_{OXA-258a}$
114	2002	ST 165 (*A. insuavis*)[a]	+	*bla*$_{OXA-243e}$
319	1996	ST 43 (*A. ruhlandii*)[a]	+	*bla*$_{OXA-258b}$
336	2010	ST 164 (*A. dolens*)[a]	+	*bla*$_{OXA-364a}$
A1	2004	*A. xylosoxidans*	+	*bla*$_{OXA-114g}$
A2	1995	*A. xylosoxidans*	+	*bla*$_{OXA-114i}$
A3	2006	*A. xylosoxidans*	+	*bla*$_{OXA-114f}$
A4	2003	*A. xylosoxidans*	+	*bla*$_{OXA-114g}$
A5	2002	*A. xylosoxidans*	+	*bla*$_{OXA-114l}$
A6	2007	*A. xylosoxidans*	+	*bla*$_{OXA-114f}$
A7	2007	*A. xylosoxidans*	+	*bla*$_{OXA-114c}$
A8	2008	*A. xylosoxidans*	+	*bla*$_{OXA-114f}$
A9	2008	*A. xylosoxidans*	+	*bla*$_{OXA-114l}$
A10	2008	*A. xylosoxidans*	+	*bla*$_{OXA-114f}$
A11	2008	*A. xylosoxidans*	+	*bla*$_{OXA-114f}$
A12	2008	*A. xylosoxidans*	+	*bla*$_{OXA-114e}$
A13	2008	*A. xylosoxidans*	+	*bla*$_{OXA-114l}$
A14	2001	*A. xylosoxidans*	+	*bla*$_{OXA-114c}$
A15	2001	*A. xylosoxidans*	+	*bla*$_{OXA-114c}$
A16	2007	*A. xylosoxidans*	+	*bla*$_{OXA-114f}$
A17	2006	*A. xylosoxidans*	+	*bla*$_{OXA-114a}$
A18	2006	*A. xylosoxidans*	+	*bla*$_{OXA-114a}$
A19	2007	*A. xylosoxidans*	+	*bla*$_{OXA-114i}$
A20	1996	*A. xylosoxidans*	+	*bla*$_{OXA-114o}$

[a] Isolates identified by ST analysis. Data published previously[14,19].

and Denmark[11], *A. xylosoxidans* was the most frequently recovered species from the airways of patients with cystic fibrosis. *A. ruhlandii*, the second most prevalent species identified in this study, was only identified in 3/96 patients in the UK and none in Spain and France; however it was the second most prevalent species in the USA and Brazil. The reported prevalence for *A. dolens* varies between 2 to 17%, accounting for 10% in the present study. Discrepant results were observed in species prevalence in different countries, the local distribution being more similar to that reported in Brazil.

All isolates included in this study were resistant to quinolones and aminoglycosides, while piperacillin, piperacillin/tazobactam and carbapenems were the most active antibiotics, as it had been previously described by Almuzara et al.[1] Fifty percent (50%) of the isolates were resistant to trimethoprim-sulfamethoxazole while 85% were resistant to colistin. Moreover, 3/7 *A. ruhlandii* isolates and 1/26 *A. xylosoxidans* were resistant to imipenem. Antimicrobial MIC values for the *Achromobacter* isolates included in this study are shown in table S2 (supplementary material).

Conclusions

Although *A. xylosoxidans* was the most common species recovered from the clinical samples of patients with CF, it

was not the only species present in those samples, as it was inferred from the phenotypic approaches analyzed in this study. *A. ruhlandii* was the second species in prevalence, in agreement with the results obtained in Brazil and USA.

MALDI-TOF rendered inconclusive or misleading results understating the presence of species other than *A. xylosoxidans*, probably due to commercial databases, key components of MALDI-TOF platforms, which are constructed with a low number of isolates mainly corresponding to *A. xylosoxidans*. Their expansion should be crucial to resolve many of the current inadequate identifications, improving the usefulness of this technique.

On the other hand, concordant results were achieved with *nrdA* sequencing or ST analysis, and the bla_{OXA} sequencing approach proposed by Traglia et al.[19], allowing a reliable discrimination among the different *Achromobacter* species, and demonstrating that a wide diversity of *Achromobacter* spp. may colonize and/or infect the airways of patients with CF. Although the MLST scheme constitutes an accurate tool, its arduous procedure may not be applicable in moderate complexity laboratories. In this regard, the amplification and sequencing of a single gene, *nrdA* or bla_{OXA}, may be more pertinent.

The susceptibility profile of *Achromobacter* spp. indicated that these microorganisms were resistant to a wide range of antibiotics, including fluoroquinolones, aminoglycosides and the majority of broad-spectrum β-lactams. Carbapenems were the most active antibiotics; however, the emergence of resistant isolates was detected. No correlation could be established among the susceptibility profiles and *Achromobacter* species. Therefore, the antimicrobial therapy in patients with CF should be conducted based on the susceptibility profile of individual *Achromobacter* spp. isolates.

Finally, prompt and accurate identification tools should provide an opportunity to understand the clinical impact of the different *Achromobacter* species on the progression of respiratory infections in patients with CF. In this sense, the development of a robust MALDI-TOF database should be desirable.

Ethical approval

Not required.

Funding sources

Conflict of interest

The authors declare that they have no conflicts of interest.

Appendix A. Supplementary data

References

1. Almuzara M, Limansky A, Ballerini V, Galanternik L, Famiglietti A, Vay C. In vitro susceptibility of *Achromobacter* spp. isolates: comparison of disk diffusion Etest and agar dilution methods. Int J Antimicrob Agents. 2010;35:68–71.

2. Amoureux L, Bador J, Bounoua Zouak F, Chapuis A, de Curraize C, Neuwirth C. Distribution of the species of *Achromobacter* in a French Cystic Fibrosis Centre and multilocus sequence typing analysis reveal the predominance of *A. xylosoxidans* and clonal relationships between some clinical and environmental isolates. J Cyst Fibros. 2016;15:486–94.

3. Amoureux L, Bador J, Siebor E, Taillefumier N, Fanton A, Neuwirth C. Epidemiology and resistance of *Achromobacter xylosoxidans* from cystic fibrosis patients in Dijon Burgundy: first French data. J Cyst Fibros. 2013;12:170–6.

4. Barrado L, Branas P, Orellana MA, Martinez MT, Garcia G, Otero JR, Chaves F. Molecular characterization of *Achromobacter* isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid, Spain. J Clin Microbiol. 2013;51:1927–30.

5. Clinical and Laboratory Standards Institute. Interpretative criteria for identification of bacteria and fungi by DNA target sequencing; approved guideline. CLSI document MM18-A. Pennsylvania, USA: CaLS Institute; 2008.

6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests. 27th ed. Wayne, PA: CLSI supplement M100; 2017.

7. Coward A, Kenna DT, Perry C, Martin K, Doumith M, Turton JF. Use of *nrdA* gene sequence clustering to estimate the prevalence of different *Achromobacter* species among cystic fibrosis patients in the UK. J Cyst Fibros. 2016;15:479–85.

8. De Bel A, Wybo I, Vandoorslaer K, Rosseel P, Lauwers S, Pierard D. Acceptance criteria for identification results of gram-negative rods by mass spectrometry. J Med Microbiol. 2011;60:684–6.

9. Doi Y, Poirel L, Paterson DL, Nordmann P. Characterization of a naturally occurring class D β-lactamase from *Achromobacter xylosoxidans*. Antimicrob Agents Chemother. 2008;52:1952–6.

10. Firmida MC, Pereira RH, Silva EA, Marques EA, Lopes AJ. Clinical impact of *Achromobacter xylosoxidans* colonization/infection on patients with cystic fibrosis. Braz J Med Biol Res. 2016;49:e5097.

11. Gade SS, Norskov-Lauritsen N, Ridderberg W. Prevalence and species distribution of *Achromobacter* sp. cultured from cystic fibrosis patients attending the Aarhus centre in Denmark. J Med Microbiol. 2017;66:686–9.

12. Liu L, Coenye T, Burns JL, Whitby PW, Stull TL, LiPuma JJ. Ribosomal DNA-directed PCR for identification of *Achromobacter* (*Alcaligenes*) *xylosoxidans* recovered from sputum samples from cystic fibrosis patients. J Clin Microbiol. 2002;40:1210–3.

13. Marchesi JR, Sato T, Weightman AJ, Martin TA, Fry JC, Hiom SJ, Dymock D, Wade WG. Design and evaluation of useful bacterium-specific PCR primers that amplify genes coding for bacterial 16S rRNA. Appl Environ Microbiol. 1998;64:795–9.

14. Papalia M, Almuzara M, Cejas D, Traglia G, Ramirez MS, Galanternik L, Vay C, Gutkind G, Radice M. OXA-258 from *Achromobacter ruhlandii*: a species-specific marker. J Clin Microbiol. 2013;51:1602–5.

15. Ridderberg W, Wang M, Norskov-Lauritsen N. Multilocus sequence analysis of isolates of *Achromobacter* from patients

with cystic fibrosis reveals infecting species other than *Achromobacter xylosoxidans*. J Clin Microbiol. 2012;50:2688–94.

16. Rodrigues ER, Ferreira AG, Leao RS, Leite CC, Carvalho-Assef AP, Albano RM, Marques EA. Characterization of *Achromobacter* species in cystic fibrosis patients: comparison of *bla*(OXA-114) PCR amplification, multilocus sequence typing, and matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2015;53:3894–6.

17. Spilker T, Vandamme P, Lipuma JJ. Identification and distribution of *Achromobacter* species in cystic fibrosis. J Cyst Fibros. 2013;12:298–301.

18. Spilker T, Vandamme P, Lipuma JJ. A multilocus sequence typing scheme implies population structure and reveals several putative novel *Achromobacter* species. J Clin Microbiol. 2012;50:3010–5.

19. Traglia G, Papalia M, Almuzara M, Gutkind G, Centron D, Vay C, Radice M, Ramirez MS. Presence of OXA-type enzymes in *Achromobacter insuavis* and *A. dolens*. Curr Microbiol. 2014;69:501–6.

20. Trancassini M, Iebba V, Citera N, Tuccio V, Magni A, Varesi P, De Biase RV, Totino V, Santangelo F, Gagliardi A, Schippa S. Outbreak of *Achromobacter xylosoxidans* in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains. Front Microbiol. 2014;5:138.

21. Turton JF, Mustafa N, Shah J, Hampton CV, Pike R, Kenna DT. Identification of *Achromobacter xylosoxidans* by detection of the *bla*(OXA-114-like) gene intrinsic in this species. Diagn Microbiol Infect Dis. 2011;70:408–11.

22. Vandamme P, Moore ER, Cnockaert M, De Brandt E, Svensson-Stadler L, Houf K, Spilker T, Lipuma JJ. *Achromobacter animicus* sp. nov., *Achromobacter mucicolens* sp. nov., *Achromobacter pulmonis* sp. nov. and *Achromobacter spiritinus* sp. nov., from human clinical samples. Syst Appl Microbiol. 2013;36: 1–10.

23. Yabuuchi E, Kawamura Y, Kosako Y, Ezaki T. Emendation of genus *Achromobacter* and *Achromobacter xylosoxidans* (Yabuuchi and Yano) and proposal of *Achromobacter ruhlandii* (Packer and Vishniac) comb. nov., *Achromobacter piechaudii* (Kiredjian et al.) comb. nov., and *Achromobacter xylosoxidans subsp. denitrificans* (Ruger and Tan) comb. nov. Microbiol Immunol. 1998;42:429–38.